N-BOC-L-天冬氨酸 1-甲基酯 | 98045-03-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-BOC-L-天冬氨酸 1-甲基酯
• 中文别名: N-叔丁氧羰基-L-天门冬氨酸1-甲酯；N-BOC-L-天冬氨酸1-甲基酯；Boc-L-天冬氨酸-1-甲酯；N-叔丁氧羰基-L-天门冬氨酸 1-甲酯
• 英文名称: α-methyl N-(tert-butoxycarbonyl)aspartate
• 英文别名: Boc-Asp-OMe；(S)-3-((tert-butoxycarbonyl)amino)-4-methoxy-4-oxobutanoic acid；Boc-L-Asp-OMe；(3S)-4-methoxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
• CAS: 98045-03-5
• 化学式: C₁₀H₁₇NO₆
• 分子量: 247.248
• InChiKey: IWFIVTBTZUCTQH-LURJTMIESA-N

物化性质

• 熔点：
  79-81℃
• 沸点：
  407.1±40.0 °C(Predicted)
• 密度：
  1.209

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-BOC-L-Aspartic acid, 1-methyl ester
(3S)-3-{[(tert-butoxy)carbonyl]amino}-4-methoxy-4-oxobutanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-BOC-L-Aspartic acid, 1-methyl ester
CAS number: 98045-03-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H17NO6
Molecular weight: 247.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Boc-Asp-OMe是一种天冬氨酸衍生物[1]。

反应信息

• 作为反应物：
  描述：

  N-BOC-L-天冬氨酸 1-甲基酯 在 N-甲基吗啉 、 4 A molecular sieve 、 pyridinium chlorochromate 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.09h， 生成 methyl (S)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoate
  参考文献：
  名称：

  碳链糖基氨基酸新家族的Hantzsch型三组分方法。C-糖基甲基吡啶基丙氨酸的合成† ，‡

  摘要：

  本文报道的C-糖基甲基吡啶基丙氨酸构成了一个新的糖基氨基酸家族，其中包含连接碳水化合物和氨基酸残基的吡啶环。这些氨基酸可用于制备通过刚性和高度稳定的系链显示牢固结合的碳水化合物片段的非天然糖肽。通过使用醛-酮酸酯-烯胺酯系统的热诱导汉茨型环缩合，已经开辟了通往这些新杂合分子的可行途径。在这些试剂之一上连接一个C-糖基残基，而另一个残基结合了一个氨基酸片段。在单锅法优化方法中，未分离出二氢吡啶，而使用聚合物负载的清除剂通过去除未反应的物质和副产物进行纯化。然后用聚合物结合的氧化剂将二氢吡啶（非对映异构体的混合物）氧化，得到带有两个生物活性残基的目标吡啶。通过这种方法，制备了八种化合物（收率58-68％），其中多样性的元素是（i）吡喃糖环的葡萄糖和半乳糖构型，（ii）异头异构体的α-和β-构型（iii）吡啶环中碳水化合物和氨基酸部分的位置。

  DOI：

  10.1021/jo071221r
• 作为产物：
  描述：

  (S)-n-boc-氮杂丁烷-2-羧酸甲酯 在 ruthenium(IV) oxide 、 sodium periodate 作用下， 以 叔丁醇 为溶剂， 反应 288.0h， 以68%的产率得到N-BOC-L-天冬氨酸 1-甲基酯
  参考文献：
  名称：

  单层方法用四氧化钌氧化环状N-酰基胺：形成ω-氨基酸

  摘要：

  含叔丁醇作为单层系统的10％NaIO 4水溶液对环N-酰基胺的四氧化钌氧化导致环内C-N键断裂，从而提供ω-氨基酸，几乎是唯一的产物。良好的收率，同时使用NaIO 4水溶液和乙酸乙酯在双层下进行类似的氧化，得到N-酰基内酰胺。

  DOI：

  10.1016/j.tetlet.2008.02.127
• 作为试剂：
  描述：

  2,3,4,6-tetra-O-benzyl-D-glucopyranose trichloroacetimidate 、 叔丁醇 在 magnesium bromide ethyl etherate 、 N-BOC-L-天冬氨酸 1-甲基酯 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以83.486%的产率得到
  参考文献：
  名称：

  Combined Lewis acid and Brønsted acid-mediated reactivity of glycosyl trichloroacetimidate donors

  摘要：

  Biomimetic conditions for a synthetic glycosylation reaction, inspired by the highly conserved functionality of carbohydrate active enzymes, were explored. At the outset, we sought to generate proof of principle for this approach to developing catalytic systems for glycosylation. However, control reactions and subsequent kinetic studies showed that a stoichiometric, irreversible reaction of the catalyst and glycosyl donor was occurring, with a remarkable rate variance depending upon the structure of the carboxylic acid. It was subsequently found that a combination of Bronsted acid (carboxylic acid) and Lewis acid (MgBr2) was unique in catalyzing the desired glycosylation reaction. Thus, it was concluded that the two acids act synergistically to catalyze the desired transformation. The role of the catalytic components was tested with a number of control reactions and based on these studies a mechanism is proposed herein. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.carres.2013.09.011

文献信息

• Novel diarylalkene derivatives and novel diarylalkane derivatives
  申请人：AJINOMOTO CO., INC.

  公开号：US20040167118A1

  公开（公告）日：2004-08-26

  The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: 1 wherein, A represents CH═CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V—W represents C═C, etc., n represents 0 to 3, Y1 represents O etc., B represents —(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents —CO—, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, —COR18a, —COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

  该发明涉及以下一般式（1）或其类似物所代表的化合物，该化合物选择性地抑制N型钙通道或其类似物，并涉及将该一般式（1）或其类似物所代表的化合物用于需要此类治疗的患者的治疗方法： 1 其中，A代表CH═CH等，a、b、c和d代表CH等，R1、R2、R3、R4、R5和R6代表H等，V—W代表C═C等，n代表0至3，Y1代表O等，B代表—(CH2)vCHR21，其中v为0至3，R21代表H、较低的烷基基团或类似物等，G代表—CO—、共价键等，m为0至6，R7和R8代表H、较低的烷基基团、—COR18a、—COOR20，其中R18a和R20各自代表较低的烷基基团或类似物等。
• [EN] NOVEL HISTONE METHYLTRANSFERASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS D'HISTONE MÉTHYLTRANSFÉRASES
  申请人：UNIV FREIBURG ALBERT LUDWIGS

  公开号：WO2021053158A1

  公开（公告）日：2021-03-25

  The present invention relates to novel compounds of formula (I) as defined herein. The compounds are inhibitors of histone methyltransferases of the seven-beta-strand family, in particular of KMT9.

  本发明涉及式(I)定义的新的化合物。这些化合物是七-β-链家族组蛋白甲基转移酶的抑制剂，特别是KMT9的抑制剂。
• Glutaminase inhibitory compounds, compositions, and methods of use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05552427A1

  公开（公告）日：1996-09-03

  There is disclosed a pharmaceutical composition for inhibiting glutaminase which comprises a imidazole derivative or a salt thereof. This compound selectively inhibits the proliferation of tumor cells, and the composition is useful as an anti-cancer agent. There is also disclosed a imidazole derivative having glutaminase inhibitory activity.

  揭示了一种用于抑制谷氨酸酶的药物组合物，包括一种咪唑衍生物或其盐。该化合物选择性地抑制肿瘤细胞的增殖，该组合物可用作抗癌剂。还揭示了一种具有谷氨酸酶抑制活性的咪唑衍生物。
• A class of novel nitronyl nitroxide labeling basic and acidic amino acids: Synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations
  作者：Jianwei Zhang、Ming Zhao、Guohui Cui、Shiqi Peng

  DOI：10.1016/j.bmc.2008.01.022

  日期：2008.4.1

  beta-carboxyl of L-Asp-OH and the gamma-carboxyl of L-Glu-OH with ethylamino as a linker. It was explored that the synthetic 30 novel ESR labeling amino acid derivatives were stable enough to the reaction conditions of peptide synthesis. Their incorporation led to 12 novel ESR optionally labeling PAK, RGDS, RGDV, and ECG. A series of NO related chemical tests, the in vitro and in vivo assays of these

  瞄准任选的ESR标记，将2-（4'-羟基）苯基-4,4,5,5-四甲基咪唑啉-3-氧化物-1-氧基引入到L-Arg-OH的胍基中，以甲基羧基为连接基的L-Lys-OH，和以乙氨基为连接基的L-Asp-OH的β-羧基和L-Glu-OH的γ-羧基。研究表明，合成的30种新型ESR标记氨基酸衍生物对肽合成的反应条件足够稳定。他们的加入导致了12种新颖的ESR，可选地标记了PAK，RGDS，RGDV和ECG。一系列与NO相关的化学测试，这些肽的体外和体内测定证实了该策略是可行的。
• Non-glutamate Type Pyrrolo[2,3-d]pyrimidine Antifolates. III. Synthesis and Biological Properties of N.OMEGA.-Masked Ornithine Analogs.
  作者：Fumio ITOH、Yoshio YOSHIOKA、Koichi YUKISHIGE、Sei YOSHIDA、Koichiro OOTSU、Hiroshi AKIMOTO

  DOI：10.1248/cpb.48.1270

  日期：——

  The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-g lutamic acid (1b, TNP-351) and the related compound (1a), was replaced with various N(omega)-acyl-, sulfonyl-, carbamoyl- and aryl-2,omega-diaminoalkanoic acids, and the inhibitory effects of the resulting products (9, 11, 14, 18, 21, 23, 25, 30, 36) on dihydrofolate reductase (DHFR), the growth of

  N- [4- [3-（2,4-二氨基-7H-吡咯并[2,3-d]嘧啶-5-基）丙基]苯甲酰基] -Lg谷氨酸的谷氨酸部分（1b，TNP-351 ）和相关化合物（1a）替换为各种N（ω）-酰基-，磺酰基-，氨基甲酰基-和芳基-2，ω-二氨基链烷酸，以及所得产物的抑制作用（9、11、14分别在二氢叶酸还原酶（DHFR）上检测了18、21、23、25、30、36），小鼠纤维肉瘤Meth A细胞和耐甲氨蝶呤的人CCRF-CEM细胞的生长。通过偶合吡咯并[2,3-d]嘧啶羧酸（7a，b）和N（ω）-邻苯二甲酰基2，ω-二氨基链烷酸甲酯（6a-）有效地合成了被半邻苯二甲酰基化的化合物（9a-f） c）和随后的水解。其他N（ω）-酰基和磺酰基-鸟氨酸类似物（21，23，25）通过酰化衍生自叔丁氧基羰基鸟氨酸类似物（17a，b）的游离氨基中间体（19a，b）而合成。游离鸟氨酸类似物（18）不能强烈抑制Meth